Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc (INGN) is a pioneering medical technology company specializing in portable oxygen concentrators for respiratory care. This dedicated news hub provides investors and healthcare professionals with essential updates on product developments, regulatory milestones, and strategic initiatives.
Access timely announcements including quarterly earnings reports, FDA clearances for new devices, partnership agreements with healthcare providers, and clinical study results. Our curated collection ensures you stay informed about innovations in oxygen therapy technology and market expansion efforts.
Key focus areas include advancements in lightweight oxygen systems, international distribution updates, and operational developments impacting respiratory patient care. Bookmark this page for direct access to primary source materials and analyzed updates from INGN's corporate communications.
Inogen reported a total revenue of $105.4 million for Q3 2022, marking a 13.2% increase year-over-year compared to $93.1 million in Q3 2021. On a constant currency basis, revenue growth was 14.5%. However, the company faced a GAAP net loss of $9.5 million and an adjusted net loss of $4.1 million. Total operating expenses rose 28.5% to $53.1 million. Despite these challenges, Inogen maintains a robust cash position of $209.6 million with no debt. For Q4 2022, revenue guidance is projected between $87 million and $92 million, indicating a potential growth of 14% to 20%.
Inogen, Inc. (NASDAQ: INGN), a medical technology company specializing in homecare respiratory products, will announce its third quarter 2022 financial results on November 2, 2022, before the market opens. A conference call is scheduled for 5:30 am PT / 8:30 am ET on the same day, accessible via US domestic and international dialing. Investors can also tune in to a live webcast on Inogen's Investor Relations website. A replay will be available after the call until November 16, 2022, using the provided contact details.
Inogen, a medical technology company, reported total revenue of $103.4 million for Q2 2022, an increase of 1.8% year-over-year. On a constant currency basis, revenue rose 3.6%. The company experienced a net loss of $3.4 million, contrasting with a net income of $5.1 million in Q2 2021. Despite challenges, Inogen maintains a strong cash position of $223.6 million. For Q3 2022, revenue guidance is projected between $97 million and $100 million, reflecting a potential growth of 4% to 7% year-over-year.
Inogen, Inc. (Nasdaq: INGN) announced it will release its second quarter 2022 financial results on August 4, 2022. A conference call will be held at 2:00 pm PT/5:00 pm ET for discussion of the results. US callers can dial (877) 841-3961, while international callers should use (201) 689-8589. The call will also be available as a replay starting August 4, 2022, at 4:00 pm PT to August 18, 2022. Inogen specializes in innovative respiratory products, particularly portable oxygen concentrators for chronic respiratory conditions.
Inogen, Inc. has appointed Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, effective May 23, 2022. CEO Nabil Shabshab expressed enthusiasm about Agnes's extensive experience in medical technology and life sciences, emphasizing her skill in engaging with shareholders. Agnes has previously held investor relations roles at Butterfly Network, Fluidigm, and ResMed, and she holds an MBA from Kellogg School of Management. This appointment aims to enhance Inogen's strategic capabilities and drive shareholder value.
Inogen, Inc. reported Q1 2022 total revenue of $80.4 million, down 7.5% year-over-year due to supply chain issues. However, revenue increased 5.2% sequentially from Q4 2021. Domestic direct-to-consumer sales rose 12.2% to $34.4 million, while business-to-business sales dropped 83.4% to $5.1 million. International business-to-business revenue surged 77.7% to $27.9 million. A net loss of $14.2 million was reported, with adjusted loss per diluted share of $0.39. The company did not provide revenue guidance for 2022, citing ongoing market uncertainties.
Sommetrics, focused on enhancing sleep health, reported key Q1 2022 achievements, notably advancing clinical activities for FDA clearance of aerSleep® II, a non-invasive treatment for obstructive sleep apnea. The six-month SUPRA pivotal trial is ongoing at various U.S. sleep centers, with promising safety data. Recent patent approvals in the U.S. and Japan bolster its intellectual property, totaling 36 patents. The company is targeting $16 million in its Series C financing, raising $11 million so far. Scott Wilkinson, former Inogen CEO, has been appointed as Advisor to guide aerSleep® II's market entry.
Inogen, Inc (NASDAQ: INGN) announced its first quarter 2022 financial results will be released after market close on
Inogen, a medical technology company specializing in homecare respiratory products, announced its participation in the 21st Annual Needham Virtual Healthcare Conference. CEO Nabil Shabshab and CFO Kristin Caltrider are set to present on April 13, 2021, at 12:45 p.m. ET. Interested parties can access the live webcast on Inogen's Investor Relations page. The presentation will be available for replay for 90 days following the event. Inogen is known for developing portable oxygen concentrators aimed at patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) announced participation in the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 4:30 p.m. ET. The company's President and CEO, Nabil Shabshab, and CFO, Kristin Caltrider, will present at the event. A webcast will be available on the Inogen Investor Relations website, with a replay accessible for 90 days post-presentation. Inogen specializes in developing and marketing portable oxygen concentrators for chronic respiratory conditions, aiming to enhance homecare solutions for patients.
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
